Difference between revisions of "Cisplatin (Platinol)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Irritant chemotherapy" to "Category:Irritant") Tags: mobile edit mobile web edit |
m |
||
| Line 18: | Line 18: | ||
*[[Cholangiocarcinoma]] | *[[Cholangiocarcinoma]] | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
| + | *[[Endometrial cancer]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
*[[Extranodal NK- and T-cell lymphoma, nasal type]] | *[[Extranodal NK- and T-cell lymphoma, nasal type]] | ||
| Line 43: | Line 44: | ||
*[[Thymoma]] | *[[Thymoma]] | ||
*[[Transformed lymphoma]] | *[[Transformed lymphoma]] | ||
| − | *[[ | + | *[[Upper tract urothelial carcinoma]] |
*[[Vulvar cancer]] | *[[Vulvar cancer]] | ||
</div> | </div> | ||
| Line 162: | Line 163: | ||
[[Category:Cholangiocarcinoma medications]] | [[Category:Cholangiocarcinoma medications]] | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
| + | [[Category:Endometrial cancer medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
[[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]] | [[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]] | ||
| Line 187: | Line 189: | ||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
[[Category:Transformed lymphoma medications]] | [[Category:Transformed lymphoma medications]] | ||
| − | [[Category: | + | [[Category:Upper tract urothelial carcinoma medications]] |
[[Category:Vulvar cancer medications]] | [[Category:Vulvar cancer medications]] | ||
[[Category:FDA approved in 1978]] | [[Category:FDA approved in 1978]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 00:25, 1 November 2020
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV, intracavitary (intraperitoneal)
Extravasation: vesicant (concentration ≥0.5 mg/mL)/irritant (concentration <0.5 mg/mL)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adenocarcinoma of unknown primary
- Adrenocortical carcinoma
- Anal cancer
- Anaplastic large cell lymphoma
- Cutaneous basal cell carcinoma
- Bladder cancer
- Breast cancer
- Cervical cancer
- Cholangiocarcinoma
- Diffuse large B-cell lymphoma
- Endometrial cancer
- Esophageal cancer
- Extranodal NK- and T-cell lymphoma, nasal type
- Gastric cancer
- Head and neck cancer
- Hepatoblastoma
- Hodgkin lymphoma
- Low-grade glioma
- Mantle cell lymphoma
- Melanoma
- Mesothelioma
- Multiple myeloma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Pancreatic cancer
- Penile cancer
- Peripheral T-cell lymphoma
- Primary mediastinal B-cell lymphoma
- SCC of unknown primary
- Small cell lung cancer
- Cutaneous squamous cell carcinoma
- Testicular cancer
- Thymoma
- Transformed lymphoma
- Upper tract urothelial carcinoma
- Vulvar cancer
Patient drug information
- Cisplatin (Platinol) patient drug information (Chemocare)[3]
- Cisplatin (Platinol) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/19/1978: Initial FDA approval
Also known as
- Code name: NSC 119875
- Generic names: CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Abiplatin | Axiplat | Biocisplatinum | Bioplatino | Blastolem | Briplatin | Brisplatin | C-Platin |
| Ceplatin | Ciplatan | Ciplexal | Cis-GRY | Cismaplat | Cispatin | Cisplamerck | Cisplan |
| Cisplasol | Cisplatex | Cisplatine | Cisplatino | Cisplatyl | Cisteen | Citoplatino | Citosin |
| Cysplatyna | Cytoplatin | Docistin | Elvecis | Fauldcispla | Ifapla | Kemoplat | Lederplatin |
| Metaplatin | Neoplat | Neoplatin | Noveldexis | Oncoplatin AQ | Peyrone's Chloride | Peyrone's Salt | Placis |
| Plastistil | Platamin | Platamine | Platiblastin | Platicis | Platidiam | Platikem | Platil |
| Platimit | Platin | Platinex | Platinil | Platino II Filaxis | Platinol | Platinox | Platinoxan |
| Platiran | Platistil | Platistin | Platistine | Platosin | Randa | Romcis | Sicatem |
| Sinplatin | Sisplanil | Tecnoplatin | Tisplal | Unistin | |||
References
Categories:
- Drugs
- Intravenous medications
- Intracavitary medications
- Vesicant
- Irritant
- Platinum agents
- Alkylating agents
- Adenocarcinoma of unknown primary medications
- Adrenocortical carcinoma medications
- Anal cancer medications
- Anaplastic large cell lymphoma medications
- Cutaneous basal cell carcinoma medications
- Bladder cancer medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Esophageal cancer medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Gastric cancer medications
- Head and neck cancer medications
- Hepatoblastoma medications
- Hodgkin lymphoma medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Melanoma medications
- Mesothelioma medications
- Multiple myeloma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- SCC of unknown primary medications
- Small cell lung cancer medications
- Cutaneous squamous cell carcinoma medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Upper tract urothelial carcinoma medications
- Vulvar cancer medications
- FDA approved in 1978
- WHO Essential Cancer Medicine